CGON vs ESTA: fair value comparison
CG Oncology, Inc. and Establishment Labs Holdings Inc. · Updated 2026-10-19
CGON has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. ESTA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, CGON currently ranks higher by quality score.
| CGON | ESTA | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $59.85 | $59.18 |
| 12-month range | $37.37–$80.68 | $47.80–$95.65 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #154 of 301 Healthcare | #156 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Low | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | — | High |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Downtrend |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: CGON fair value analysis · ESTA fair value analysis